Acadia Pharma (ACAD): No NUPLAZID Data Until Mid 2017 - HC Wainwright

September 23, 2016 8:38 AM EDT
Get Alerts ACAD Hot Sheet
Price: $22.60 -2.5%

Rating Summary:
    8 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 25 | New: 8
Trade ACAD Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

H.C. Wainwright analyst, Andrew Fein, reiterated his Buy on Acadia Pharmaceuticals (NASDAQ: ACAD) after meeting with management but noted that he expects management to wait to provide metrics on how the launch is progressing toward the middle of 2017. This should lead to a tightening of consensus for 2H17.

No change to the price target of $60.00

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $34.98 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

H.C. Wainwright

Add Your Comment